DRUG Latest Quarter's Earnings
| Announce Date | 05/15/2025 |
| EPS Normalized Actual | $-0.29 (Beat by $0.1) |
| EPS GAAP Actual | $-0.29 (Beat by $0.1) |
| Revenue Actual | $0B |
| Revenue Surprise | Beat by $0M |
Upcoming Quarter's Earnings
| Announce Date | 09/30/2025 (Pre-Market) |
| EPS Normalized Estimate | $-1.08668 |
| EPS GAAP Estimate | $-1.08668 |
| Revenue Estimate | $0B |
Annual EPS Estimate
| Fiscal Period Ending | EPS Estimate | Forward PE | Low | High | # of Analysts |
|---|---|---|---|---|---|
| Sep 2029 | -7.57739 | -4.44 | -7.57739 | -7.57739 | 1 |
| Sep 2028 | -6.62674 | -5.07 | -6.62674 | -6.62674 | 1 |
Quarterly EPS History
| Period | EPS | Beat / Miss | Revenue | YoY | Beat / Miss |
|---|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | -0.42 | 0.51655 | 0B | NAN% | 0M |
| FQ4 2024 (Dec 2024) | 0.0111 | -2.08087 | 0B | NAN% | 0M |
| FQ3 2024 (Sep 2024) | 0 | -1.82214 | 0B | NAN% | 0M |
| FQ2 2024 (Jun 2024) | 0.0515 | 0.0515 | 0B | NAN% | 0M |
| FQ1 2024 (Mar 2024) | -0.13 | -0.13 | 0B | NAN% | 0M |
| FQ4 2023 (Dec 2023) | -0.44 | -0.44 | 0B | NAN% | 0M |
| FQ3 2023 (Sep 2023) | -0.41 | -0.41 | 0B | NAN% | 0M |
| FQ2 2023 (Jun 2023) | -1.93 | -1.93 | 0B | NAN% | 0M |
Quarterly Estimates Summary
FQ4 Announce Date
09/30/2025 (Pre-Market)
Consensus EPS Estimates
-1.08668
Consensus Revenue Estimates
0B
Consensus EPS Estimates
| Fiscal Period Ending | EPS Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ2 2027 (Jun 2027) | -1.10245 | -- | -1.10245 | -1.10245 | 1 |
| FQ1 2027 (Mar 2027) | -1.09543 | -- | -1.09543 | -1.09543 | 1 |
| FQ4 2026 (Dec 2026) | -1.14459 | -- | -1.14459 | -1.14459 | 1 |
| FQ2 2026 (Jun 2026) | -0.6092 | -- | -0.6092 | -0.6092 | 1 |
| FQ1 2026 (Mar 2026) | -0.50264 | 16.44 | -0.50264 | -0.50264 | 1 |
| FQ4 2025 (Dec 2025) | -0.40073 | 102.77 | -0.40073 | -0.40073 | 1 |
| FQ3 2025 (Sep 2025) | -1.08668 | -- | -1.08668 | -1.08668 | 1 |
Consensus Revenue Estimates
| Fiscal Period Ending | Revenue Estimate | YoY Growth(%) | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ2 2027 (Jun 2027) | 0B | -- | 0B | 0B | 0 |
| FQ1 2027 (Mar 2027) | 0B | -- | 0B | 0B | 0 |
| FQ4 2026 (Dec 2026) | 0B | -- | 0B | 0B | 0 |
| FQ2 2026 (Jun 2026) | 0B | -- | 0B | 0B | 0 |
| FQ1 2026 (Mar 2026) | 0B | -- | 0B | 0B | 0 |
| FQ4 2025 (Dec 2025) | 0B | -- | 0B | 0B | 0 |
| FQ3 2025 (Sep 2025) | 0B | -- | 0B | 0B | 0 |
Quarterly Estimates Revisions
EPS # of Up Revisions
4
EPS # of Down Revisions
4
Revenue # of Up Revisions
6
Revenue # of Down Revisions
3
Consensus EPS Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Consensus Revenue Revision Trend
| Fiscal Period Ending | EPS Estimate | YoY Growth | Low | High | # of Analysts |
|---|---|---|---|---|---|
| FQ4 2021 (Dec 2021) | 0.41 | -12.52% | 0.39 | 0.48 | 20 |
| FQ1 2022 (Mar 2022) | 0.59 | 6.89% | 0.55 | 0.62 | 15 |
| FQ2 2022 (Jun 2022) | 0.70 | 2.62% | 0.61 | 0.74 | 15 |
| FQ3 2022 (Sep 2022) | 0.68 | 4.62% | 0.65 | 0.70 | 15 |
Earnings Surprise Summary
EPS # of Beats
2
EPS # of Misses
6
EPS # of in-lines
0
Revenue # of Beats
0
Revenue # of Misses
0
Revenue # of in-lines
8
Earnings Surprise (EPS) - Actual vs Consensus
| Earnings Date | EPS Estimate | EPS Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | -0.93655 | -0.42 | 0.51655 | -122.99% |
| FQ4 2024 (Dec 2024) | 2.09197 | 0.0111 | -2.08087 | -18746.58% |
| FQ3 2024 (Sep 2024) | 1.82214 | 0 | -1.82214 | -INF% |
| FQ2 2024 (Jun 2024) | 0.0515 | 0.0515 | 100% | |
| FQ1 2024 (Mar 2024) | -0.13 | -0.13 | 100% | |
| FQ4 2023 (Dec 2023) | -0.44 | -0.44 | 100% | |
| FQ3 2023 (Sep 2023) | -0.41 | -0.41 | 100% | |
| FQ2 2023 (Jun 2023) | -1.93 | -1.93 | 100% |
Revenue Surprise - Actual vs Consensus
| Earnings Date | Revenue Estimate | Revenue Actual | Surprise | Surprise % |
|---|---|---|---|---|
| FQ1 2025 (Mar 2025) | $0B | $0B | $0M | NAN% |
| FQ4 2024 (Dec 2024) | $0B | $0B | $0M | NAN% |
| FQ3 2024 (Sep 2024) | $0B | $0B | $0M | NAN% |
| FQ2 2024 (Jun 2024) | $0B | $0B | $0M | NAN% |
| FQ1 2024 (Mar 2024) | $0B | $0B | $0M | NAN% |
| FQ4 2023 (Dec 2023) | $0B | $0B | $0M | NAN% |
| FQ3 2023 (Sep 2023) | $0B | $0B | $0M | NAN% |
| FQ2 2023 (Jun 2023) | $0B | $0B | $0M | NAN% |
DRUG Ratings Summary
DRUG Quant Ranking
